Table 4 Comparison of bleeding after operation among three groups.

From: Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI

 

Group L (N = 68)

Group M (N = 218)

Group H (N = 61)

χ2

P

Bleeding gums, n (%)

3 (4.41)

15 (6.88)

5 (8.20)

0.796

0.708b

Gastrointestinal hemorrhage, n (%)

1 (1.47)

3 (1.38)

3 (4.92)

2.908

0.156a

Cerebral hemorrhage, n (%)

0 (0)

1 (0.46)

0 (0)

1.093

1.000a

Hematuria, n (%)

1 (1.47)

2 (0.92)

3 (4.92)

3.992

0.067a

Skin mucosa petechiae, n (%)

2 (2.94)

15 (6.88)

10 (16.39)*

8.772

0.012b

Total haemorrhagic cases, n (%)

7 (10.29)

36 (16.51)

21 (34.43)

13.901

0.001

  1. a: fisher's precise test; b: chi-square.
  2. *Comparison with low dose group, p < 0.05.